Top Markets
#1 Islamic Coin Islamic Coin +154.50%
#2 PulseChain PulseChain +49.22%
#3 RedStone RedStone +23.91%
#4 MarsCoin MarsCoin +12.77%
#5 Nockchain Nockchain +12.59%
#6 BOOK OF MEME BOOK OF MEME +11.85%
#7 Not in Employment, Education, or Training Not in Employment, Education, or Training +11.84%
#8 SkyAI SkyAI +8.96%
#9 Lighter Lighter +8.81%
#10 Monad Monad +8.69%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Codex DNA, Inc. Codex DNA, Inc.

Codex DNA, Inc.

DNAY
Rank in Stocks #28198
Operating in the synthetic biology sector, Codex DNA, Inc. develops,... Operating in the synthetic biology sector, Codex DNA, Inc. develops, manufactures, and sells advanced instruments, reagents, and complementary services. Its primary customer base comprises pharmaceutical firms and academic laboratories worldwide, though it also extends its offerings to government institutions, contract research organizations, and other synthetic biology companies. The company's innovative product portfolio includes the BioXp system, designed to transform digital DNA sequences into usable synthetic DNA, alongside the intuitive BioXp portal, an online platform facilitating DNA sequence design and assembly into chosen vectors. Researchers can also access BioXp kits, which supply essential building blocks and reagents, including the proprietary Gibson Assembly brand, for specific synthetic biology applications. Further support is provided through cloud-based scripts and specialized benchtop reagents for processing products generated by the BioXp system. Moreover, Codex DNA offers Biofoundry Services, allowing clients to commission and receive endpoint-ready BioXp products like genes, clones, cell-free amplified DNA, and variant libraries, in addition to providing short oligo ligation assembly enzymatic DNA synthesis. Established in 2011 and headquartered in San Diego, California, the company rebranded as Codex DNA, Inc. in March 2020, having previously been known as SGI-DNA, Inc.
Share Price
$1.30
Last synced: 2023-01-03
Market Cap
$27.96M
Change (1 day)
8.33%
Change (1 year)
0.00%
Country
US
Trade Codex DNA, Inc. (DNAY)

Category

Healthcare
P/E ratio for Codex DNA, Inc. (DNAY)
P/E ratio as of 2026 TTM: 0
According to Codex DNA, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Codex DNA, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Abbott Laboratories Abbott Laboratories
Abbott Laboratories
ABT.US
 35.77 -
US
Stryker Corporation Stryker Corporation
Stryker Corporation
SYK.US
 34.86 -
US
Medtronic plc Medtronic plc
Medtronic plc
MDT.US
 21.39 -
IE
Boston Scientific Corporation Boston Scientific Corporation
Boston Scientific Corporation
BSX.US
 20.90 -
US
Edwards Lifesciences Corporation Edwards Lifesciences Corporation
Edwards Lifesciences Corporation
EW.US
 52.64 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.